Procedure-related toxicity
| Toxicity | grade | number of patients | percentage (%) |
|---|---|---|---|
| Ischemic cholecystits | 3 | 1 | 6 |
| Carcinoid storm | 2 | 1 | 6 |
| Insulin storm | 2 | 1 | 6 |
| Postembolization syndrome 2 | 14 | 82 |
Patients’ demographic data
| Variable | Number |
|---|---|
| Number of patients included | 17 |
| Age (years) | |
| Mean | 56 |
| SD | 13.9 |
| Range | 18–82 |
| Sex | |
| M | 8 |
| F | 9 |
| Primary tumour | |
| Intestinal NET | 6 |
| Pancreatic NET | 2 |
| Pulmonary NET | 2 |
| Pancreatic insulinoma | 4 |
| Unknown | 3 |
| Surgical resection of primary tumour | |
| Intestinal NET | 5 |
| Pancreatic NET | 2 |
| Pulmonary NET | 2 |
| Pancreatic insulinoma | 1 |
| Total | 10 |
| Tumour grade (Ki-67 index) | |
| Ki-67 < 2% | 4 |
| Ki-67 2–20% | 6 |
| Ki-67 > 20% | 4 |
| Unknown | 3 |
| Tumour burden (% of total liver volume) | |
| 0–10% | 4 |
| 10–20% | 3 |
| 20–50% | 5 |
| > 50% | 5 |
| Extrahepatic metastatic disease | 16 |
| Lymphadenopathy | 7 |
| Bone | 5 |
| Lung | 3 |
| Spleen | 1 |
| Adrenal | 3 |
| Brain | 1 |
| Ovary | 2 |
| Pancreas | 2 |
| Peritoneum | 1 |
| Skin | 1 |
| Previous treatment | |
| Surgical resection of liver metastases | 1 |
| Radiofrequency ablation of liver metastases | 1 |
| Radiotherapy for brain metastases | 1 |
| Radiotherapy for bone metastases | 1 |
| Interferon | 3 |
| Everolimus | 7 |
| m-TOR-inhibitor | 1 |
| Sunitinib | 4 |
| Somatostatine analogue | 15 |
| Diazoxide | 3 |